Active substance
Ciclesonide
- SFDA 3
- US FDA 4
- Health Canada 3
- US price lines 3
- NHS prices 2
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ALVESCO 160MCG-PUFF INHALER | 160 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 52.70 | NCE · Prescription | TAKEDA GMBH | Withdrawn by MAH · Not Marketed |
| ALVESCO 160MCG-PUFF INHALER | 160 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 105.45 | NCE · Prescription | TAKEDA GMBH | Withdrawn by MAH · Not Marketed |
| ALVESCO 80MCG-PUFF INHALER | 80 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 63.00 | NCE · Prescription | TAKEDA GMBH | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OMNARIS | 0.05MG/SPRAY | spray, metered · nasal | AZURITY | Prescription | 20 Oct 2006 |
| OMNARIS | 50MCG | spray · nasal | NYCOMED US INC | Prescription | 21 Nov 2007 |
| ALVESCO | 0.08MG/INH; 0.16MG/INH | aerosol, metered · inhalation | AZURITY | Prescription | 10 Jan 2008 |
| ZETONNA | 0.037MG/INH | aerosol, metered · nasal | AZURITY | Discontinued | 20 Jan 2012 |
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ALVESCO 160 MCG INHALER | $42.97099 | per GM | 23 Sep 2026 |
| US NADAC | ALVESCO 80 MCG INHALER | $42.95871 | per GM | 23 Sep 2026 |
| US NADAC | OMNARIS 50 MCG NASAL SPRAY | $22.5531 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Ciclesonide 160micrograms/dose inhaler CFC free | £38.62 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Ciclesonide 80micrograms/dose inhaler CFC free | £32.83 | 120 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Therapeutic equivalent to budesonide for Asthma
Safety signals and safety-related labeling changes
- US FDA 16 Feb 2023 ALVESCO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Feb 2023 ZETONNA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 8 May 2019 OMNARIS — safety-related labeling change
Labeling sections changed: Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.